Ziltivekimab Drug Fails to Reduce Cardiac Events in ZEUS Trial

Novo Nordisk's ZEUS study revealed that the anti-inflammatory drug ziltivekimab, targeting IL-6, did not reduce heart attacks, strokes, or deaths compared to placebo. Despite lowering IL-6 levels, the monoclonal antibody failed to meet its primary endpoint for reducing major adverse cardiac events. These findings, presented at the American Heart Association's Scientific Sessions, are significant for cardiovascular disease research.